
Results
15
Companies which are more than 50% undervalued based on analyst price target.
15 companies
Inventiva
Market Cap: €808.1m
A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.
IVA
€3.42
7D
13.1%
1Y
29.3%
Valneva
Market Cap: €443.2m
A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
VLA
€2.34
7D
5.5%
1Y
-2.2%
Cellectis
Market Cap: €207.1m
A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.
ALCLS
€2.85
7D
14.7%
1Y
108.8%
Innate Pharma
Market Cap: €156.1m
Operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
IPH
€1.66
7D
3.7%
1Y
8.8%
Sensorion
Market Cap: €133.8m
A biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France.
ALSEN
€0.26
7D
12.1%
1Y
-25.3%
OSE Immunotherapeutics
Market Cap: €87.8m
A clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.
OSE
€3.73
7D
20.5%
1Y
-24.6%
Adocia
Market Cap: €87.1m
A clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity.
ADOC
€4.45
7D
9.7%
1Y
21.4%
ABIONYX Pharma
Market Cap: €73.4m
A biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States.
ABNX
€2.08
7D
1.5%
1Y
73.3%
AB Science
Market Cap: €61.9m
A clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France.
AB
€0.77
7D
-13.9%
1Y
-49.9%
MaaT Pharma
Market Cap: €54.3m
A late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival.
MAAT
€2.88
7D
17.6%
1Y
-43.1%
THX Pharma Société Anonyme
Market Cap: €50.8m
A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.
ALTHX
€3.68
7D
9.9%
1Y
187.5%
Nicox
Market Cap: €33.6m
Operates as an ophthalmology company in France and internationally.
ALCOX
€0.38
7D
1.9%
1Y
70.5%
Advicenne
Market Cap: €20.4m
A specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally.
ALDVI
€1.40
7D
5.3%
1Y
3.9%
Valbiotis
Market Cap: €20.1m
Engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia.
ALVAL
€0.85
7D
6.3%
1Y
3.0%
GenSight Biologics
Market Cap: €19.5m
A clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system.
SIGHT
€0.083
7D
3.6%
1Y
-37.2%